Formycon

Formycon AG is a pharmaceutical company based in Planegg, Germany, specializing in the development and marketing of biosimilar products. Founded in 1999 and formerly known as Nanohale AG, the company focuses on treatments in ophthalmology, immunology, and other chronic diseases. Its product pipeline includes several biosimilar candidates: FYB201, which targets Lucentis for neovascular age-related macular degeneration; FYB202, a candidate for Stelara aimed at treating inflammatory diseases like psoriasis and Crohn's disease; and FYB203, which is also focused on Eylea for eye conditions. Additionally, Formycon is engaged in the development of drug delivery systems and offers analytical and formulation services to the biopharmaceutical industry, covering the complete analytical development chain and supporting the manufacturing process for clinical and market medications.